

Evaluation of CPT-11 in combination with doxorubicin against pancreatic ductal adenocarcinoma PO3 on B6D2F1 female mice
BCM-887 (10.30.96-02.27.97)

Agent (batch)	Route	Dosage in mg/kg/dose	Schedule in days	Total dose in mg/kg	Fraction of HDT	Drug death (days of death)	Average body weight change in % per mouse at nadir (day of nadir)	Median tumor weight in mg on day 16 (range)	T/C in %	Time for median tumor to reach 1000 mg in days	In days	Tumor free survivors day/120	Comments
CPT-11	p.o. 0.2 ml	100.8 62.5 (2x/day)	6-9	806.4 500.0 310.4	1 0/5 0/5	0/5 -16.0 (13) -3.9 (13) -3.5 (13)	75 (0-126) 126 (32-340) 202 (0-1162)	8 14 22	26.2 25.7 20.4	9.8 9.3 4.0	1.3 1.2 0.5	0/5 0/5 0.5	HDT active Active Inactive
Doxorubicin	i.v. 0.2 ml	10.0 6.2 3.8	6-9 12.4 7.6	20.0 0/5 0/5	1 0/5 0/5	-14.1 (15) -4.4 (13) -5.1 (15)	0 (0-15) 126 (0-214) 382 (32-546)	0 14 42	25.9 23.9	9.5 7.5	1.2 1.0	4/5 0/5 0/5	HDT highly active Active Active
Doxorubicin CPT-11	i.v/0.2ml p.o/0.2ml	5.0 80.6 6.9 4.1 65.5 3.1 50.4 2.2 35.3 1.2 20.1	6.9 6.9 10.0 (2x/day) 524.0 6.2 403.2 4.4 282.4 2.4 160.8	644.8 8.2 0.8 0.41 0.65/1.06 0.31 0.50/0.81 0.22 0.35/0.57 0.12 0.20/0.32	1.3 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5	-10.3 (13) -6.9 (13) -2.5 (6) -3.9 (13) 72 (0-126) -1.8 (14) 336 (270-942) 918 (343-1444)	0 (0-0) 0 (0-0) 0 (0-0) 72 (0-126) 0 37 20.5 16.4	0 0 0 0 0 0 0 0	52.0 39.9 28.7 12.3 1.6 0.5 0.5 0/10	35.6 23.5 12.3 1.6 0.5 0.5 0/5 0/10	4.7 3.1 0/5 0/5 0/5 0/5 0/5 0/5	Highly active Highly active Active Inactive	
Control													

Tumor doubling time = 2.3 days. Mice average weight: CPT-11 = 24.39 g, doxorubicin = 25.26 g, combination = 23.50 g.
 The 2 administrations of CPT-11 were performed 4 hours apart.
 Abbreviation used: HDT = highest dose tested.

Figure 1